ArticleBMC musculoskeletal disorders2025
Natural course of patients diagnosed with nodular fasciitis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNodular fasciitis (NF) shrinks spontaneously; however, few reports have focused on its self-regression. This study investigated NF shrinkage.
methodsWe retrospectively reviewed 55 patients with NF who visited Nagoya University Hospital. Twenty-three patients were followed-up and evaluated for shrinkage. Factors affecting the occurrence of deep layers and ≥ 50% tumor volume shrinkage were investigated. The proportion of patients who achieved ≥ 50% tumor volume shrinkage, time to ≥ 50% tumor volume shrinkage, and tumor volume compared with baseline at the last follow-up were assessed.
resultsThe presence of deep layers was significantly associated with longer symptom duration and more frequent biopsies. The proportion of patients who achieved ≥ 50% tumor volume shrinkage, time to ≥ 50% tumor volume shrinkage, and tumor volume compared to baseline at the last follow-up were 17 of 23 patients (74%), median 104 days (19–973)days, and median 24% (7–99%), respectively. Shorter duration of symptoms was significantly associated with ≥ 50% tumor volume shrinkage.
conclusionApproximately three-quarters of the patients demonstrated ≥ 50% tumor volume shrinkage, suggesting that wait-and-see concept was acceptable for NF. The better understanding of NF shrinkage showed that proper follow-up is necessary for patients with NF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.